Health Economics›Neuroendocrine carcinoma›Advanced disease all lines of therapy

Advanced disease all lines of therapy

Neuroendocrine carcinoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Etoposide (EP) Variant #01	—	R 4 264	42d	—	~12.5 mo	—	—	1
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug	—	R 743	42d	—	~10.9 mo	—	—	1

2 of 2 regimens shown